How Much Weight Can You Lose on Wegovy? (2026)
**Quick answer.** On Wegovy (semaglutide) at the standard 2.4mg dose, clinical trial data shows an average weight loss of 14.9% of body weight over 68 weeks, around 15kg for someone starting at 100kg. At the new 7.2mg dose, the STEP UP trial showed an average of 20.7% weight loss over 72 weeks, with roughly one in three patients losing 25% or more of their body weight. Results vary between individuals and are strongest when treatment is paired with dietary changes and regular physical activity.
## What the clinical trials show
Two major trials give us the clearest picture of how much weight people lose on Wegovy: STEP 1, which established the 2.4mg maintenance dose, and STEP UP, which evaluated the new higher 7.2mg dose. Both were large, randomised, double-blind, placebo-controlled trials in adults without type 2 diabetes.
### STEP 1 (standard 2.4mg dose)
STEP 1 followed 1,961 adults with obesity, or overweight with a weight-related comorbidity, over 68 weeks. Participants on semaglutide 2.4mg alongside lifestyle intervention achieved:
- Average weight loss of **14.9%** of body weight, compared with 2.4% on placebo
- 86.4% lost at least 5% of their body weight
- 69.1% lost at least 10%
- 50.5% lost at least 15%
Source: STEP 1, *New England Journal of Medicine*, February 2021 (NCT03548935).
### STEP UP (new 7.2mg dose)
STEP UP followed 1,407 adults with obesity (BMI 30+) over 72 weeks. Participants were randomised 5:1:1 to semaglutide 7.2mg, 2.4mg, or placebo.
Two weight-loss figures are commonly reported for STEP UP, depending on which analysis is used. On the efficacy estimand (which reflects results in patients who took treatment as intended), semaglutide 7.2mg produced **20.7%** weight loss. On the treatment-regimen estimand (which includes all randomised patients regardless of adherence), the figure was **18.7%**. Both are valid. They answer slightly different questions, and we'll use the efficacy estimand figures below.
Primary findings at 72 weeks:
- Average weight loss at 7.2mg: 20.7%
- Average weight loss at 2.4mg (in the same trial): 17.5%
- Placebo: 2.4%
- Waist circumference reduction: 11.7cm greater than placebo
Source: STEP UP, *The Lancet Diabetes & Endocrinology*, September 2025 (NCT05646706).
Here is how categorical weight-loss outcomes compare across the two trials:
| Dose | Trial | Average loss | ≥5% | ≥10% | ≥15% | ≥20% | ≥25% |
|---|---|---|---|---|---|---|---|
| 2.4mg | STEP 1 | 14.9% | 86.4% | 69.1% | 50.5% | n/r | n/r |
| 2.4mg | STEP UP | 17.5% | 78.1% | 67.2% | 54.7% | 33.3% | 16.7% |
| 7.2mg | STEP UP | 20.7% | 90.7% | 83.5% | 74.1% | 47.7% | 33.2% |
| Placebo | STEP 1 / UP | 2.4% | n/r | n/r | n/r | n/r | n/r |
The 2.4mg figures differ slightly between STEP 1 and STEP UP because the two trials used different patient populations and protocols. Both are clinically valid. The STEP UP 2.4mg arm is the most direct comparator for the 7.2mg data because both were run in the same trial.
## What does this mean in real terms?
Percentages can feel abstract. Here is what the three main figures translate to in kilograms, for a range of starting weights:
| Starting weight | 14.9% loss (2.4mg, STEP 1) | 17.5% loss (2.4mg, STEP UP) | 20.7% loss (7.2mg, STEP UP) |
|---|---|---|---|
| 80kg | 11.9kg | 14.0kg | 16.6kg |
| 90kg | 13.4kg | 15.8kg | 18.6kg |
| 100kg | 14.9kg | 17.5kg | 20.7kg |
| 110kg | 16.4kg | 19.3kg | 22.8kg |
| 120kg | 17.9kg | 21.0kg | 24.8kg |
| 130kg | 19.4kg | 22.8kg | 26.9kg |
These are trial averages across large populations. Individual results vary considerably. The averages include both high responders, who lose substantially more, and low responders, who lose less. Your own results will sit somewhere on that distribution, and there is no reliable way to predict in advance where.
Trial participants also followed a structured lifestyle programme alongside the medication: a 500-calorie daily deficit and 150 minutes of physical activity per week. The published outcomes therefore reflect the combination of medication plus lifestyle change. Members who make dietary and activity changes alongside Wegovy consistently achieve better outcomes than those who rely on the medication alone.
## When do results happen? The timeline
Wegovy is escalated gradually from a low starting dose to the maintenance dose. This is deliberate. The starting dose is about tolerance, not weight loss. Here is what typically happens at each stage:
| Timeframe | Dose | What typically happens |
|---|---|---|
| Weeks 1–4 | 0.25mg | Adjustment phase. Appetite begins to reduce. Little weight change. |
| Month 2 | 0.5mg | Appetite suppression more pronounced. Early weight loss begins. |
| Months 3–4 | 1mg to 1.7mg | Visible weight loss for most members. Dose continuing to escalate. |
| Month 5 onwards | 2.4mg | Maintenance dose reached. Weight loss continues. |
| Month 6 onwards | 7.2mg (if indicated) | Higher dose for members who plateau on 2.4mg. |
| Months 6–12 | — | Greatest cumulative weight loss for most members. |
| Months 12–18 | — | Weight loss continues at a slower rate, approaching the lowest point. |
The highest rate of loss typically occurs during months 2 to 6, while the dose is escalating. Once the maintenance dose is reached, weight loss continues but more gradually. Most members reach their lowest weight somewhere between months 9 and 18.
Patience during the first month matters. The 0.25mg starting dose is an adjustment phase, designed to let the body tolerate the medication. It is not a therapeutic dose. People who stop during month one because they don't see immediate results are stopping before the drug has had a chance to work.
## What affects how much weight you lose on Wegovy?
Four factors account for most of the variation in outcomes.
**Starting dose and escalation.** Members who tolerate escalation to higher doses typically achieve greater weight loss. The 7.2mg dose produces meaningfully more weight loss than 2.4mg in the same trial population. It is not a first escalation, though. It is intended for members who have been on 2.4mg for several months and have plateaued.
**Diet and activity.** STEP 1 and STEP UP both used a structured lifestyle intervention alongside the medication. Wegovy reduces appetite, but the composition of what you eat still matters. Prioritising protein (to preserve muscle mass during weight loss) and reducing ultra-processed foods consistently improves outcomes. Resistance training helps preserve lean tissue.
**Individual biology.** GLP-1 receptor sensitivity varies between people. Some are strong responders at 1mg and never need to escalate further. Others reach 2.4mg and achieve modest results. This variation is biological. It is not a reflection of effort or discipline.
**Duration of treatment.** Weight loss on Wegovy continues to build through month 12 and beyond for most members. Stopping early, before reaching a therapeutic dose or before the full effect has had time to develop, significantly reduces total weight lost.
## What happens if you stop taking Wegovy?
STEP 4 followed patients who had been on Wegovy for 20 weeks and then either continued treatment or switched to placebo. Those who stopped regained approximately two-thirds of their lost weight within 12 months. This is not a personal failure. It is the expected biological response.
Obesity is a chronic condition. GLP-1 medications treat it in the same way that antihypertensives treat blood pressure: they work while you take them. When treatment stops, the underlying condition reasserts itself. Most members who achieve meaningful results on Wegovy continue treatment long-term.
If you're considering stopping, speak to your prescriber first. There may be dose-reduction options, or your prescriber may want to make sure you have appropriate support in place before stopping.
## Wegovy and Mounjaro: how do the results compare?
At standard doses, Mounjaro (tirzepatide) produced greater average weight loss than Wegovy in its respective trial: 22.5% at 15mg over 72 weeks in SURMOUNT-1, compared with 14.9% at 2.4mg over 68 weeks in STEP 1. With the new 7.2mg Wegovy dose, the gap narrows considerably: 20.7% vs 22.5%. These are separate trials with different populations and protocols, so they're most usefully read as two reference points rather than a direct head-to-head comparison.
Both medicines produce clinically significant weight loss that exceeds what is typically achievable with diet and exercise alone. The right choice depends on individual clinical factors, tolerability, cost, and personal preference. Wegovy is typically £50 to £100 per month cheaper than Mounjaro at comparable dose stages.
For a side-by-side explainer, see our guide to [what Wegovy and Mounjaro are and how they work](https://www.myfoundry.co.uk/blogs/news/what-is-wegovy-what-is-mounjaro).
## How to get Wegovy in the UK
Wegovy is available on private prescription for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related condition such as type 2 diabetes, high blood pressure, or cardiovascular disease. Adjusted BMI thresholds apply for some ethnic backgrounds in line with NICE guidance.
It is also available on the NHS through specialist weight management services for members who meet NHS criteria. Waiting times of 6 to 12 months are common in most areas.
At Foundry, the eligibility check takes around five minutes online. If you meet the criteria, a UK-registered prescriber reviews your information and, if clinically appropriate, issues the prescription. Your medication is dispensed by our GPhC-registered pharmacy partner and delivered to your door, typically within 2 to 3 working days. For a fuller picture of what the service covers, see our [complete Wegovy guide](https://www.myfoundry.co.uk/blogs/news/wegovy-uk-a-complete-patient-guide-to-semaglutide-for-weight-loss).
## A note on safety
Like all prescription medicines, Wegovy can cause side effects. The most common are nausea, diarrhoea, and constipation, which typically improve within the first few weeks. In January 2026, the MHRA updated its product information for GLP-1 and dual GLP-1/GIP medicines to highlight a small risk of severe acute pancreatitis, including rare reports of necrotising and fatal pancreatitis. Anyone experiencing severe, persistent stomach pain, particularly if it radiates to the back with nausea or vomiting, should seek urgent medical attention. Suspected side effects can be reported via the [Yellow Card scheme](https://yellowcard.mhra.gov.uk/).
## Frequently asked questions
### How much weight can I lose on Wegovy?
In the STEP 1 trial, patients on Wegovy at the standard 2.4mg dose lost an average of 14.9% of their body weight over 68 weeks, around 15kg for someone starting at 100kg. In the STEP UP trial, patients on the new 7.2mg dose lost an average of 20.7% over 72 weeks, with roughly one in three losing 25% or more. Individual results vary depending on dose, diet, activity, and personal biology.
### How long does it take to see results on Wegovy?
Most people notice reduced appetite within the first 2 to 4 weeks. Visible weight loss typically begins from month 2 or 3, as the dose escalates from the initial 0.25mg adjustment dose. The greatest rate of loss usually occurs during months 2 to 6. Results continue to build through month 12 and beyond, and most people reach their lowest weight between months 9 and 18.
### What is the new 7.2mg Wegovy dose and does it produce more weight loss?
The 7.2mg dose of Wegovy was approved for adults with obesity (BMI 30+) who need additional support after reaching the standard 2.4mg maintenance dose. In the STEP UP trial, it produced an average weight loss of 20.7% over 72 weeks, compared with 17.5% at 2.4mg in the same trial. Around one in three patients on 7.2mg lost 25% or more of their body weight. It is not a first escalation. It is intended for members who have plateaued on 2.4mg.
### How does Wegovy compare to Mounjaro for weight loss?
In their respective trials, Mounjaro produced greater average weight loss than Wegovy at standard doses: 22.5% at 15mg in SURMOUNT-1, compared with 14.9% at 2.4mg in STEP 1. At the new 7.2mg Wegovy dose, the gap narrows to 20.7% vs 22.5%. These are separate trials with different populations, so they're best read as two reference points rather than a direct head-to-head. The right choice depends on clinical factors, tolerability, and cost.
### Will I regain weight if I stop taking Wegovy?
The STEP 4 trial showed that patients who stopped Wegovy after 20 weeks regained approximately two-thirds of their lost weight within 12 months. This is a biological response, not a personal failure. Obesity is a chronic condition, and Wegovy treats it while you take it, in the same way that blood pressure medication works while you take it. Most members who achieve meaningful results continue treatment long-term. If you're considering stopping, speak to your prescriber first.
### Am I eligible for Wegovy in the UK?
On private prescription, Wegovy is available for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related condition such as type 2 diabetes, high blood pressure, or cardiovascular disease. Adjusted BMI thresholds apply for some ethnic backgrounds in line with NICE guidance. Wegovy is also available on the NHS through specialist weight management services for members who meet NHS criteria, though waiting times of 6 to 12 months are common.
## Ready to start Wegovy with a regulated UK provider?
Foundry is a CQC-regulated UK telehealth service. The eligibility check takes around five minutes. If you qualify, a UK-registered prescriber assesses your suitability and your medication is dispensed by our GPhC-registered pharmacy partner, typically delivered within 2 to 3 working days. Your price covers clinical assessment, prescribing, needles, and a sharps bin on your first order. Shipping is charged separately at checkout.
[Check your eligibility](https://www.myfoundry.co.uk/pages/start-a-consultation)
*Treatment is subject to prescriber approval and clinical suitability. Results vary between individuals. Wegovy is a prescription-only medicine.*
---
## Hand-off notes for Darren
**Data corrections made against the brief** (for review before publishing):
1. **STEP 1 headline figure.** Brief cites 15.2% at 2.4mg; Approved Clinical Citations library cites **14.9%** (primary outcome from Wilding et al., NEJM 2021). 15.2% is the STEP 5 two-year figure, not STEP 1. Used 14.9% throughout, including in the real-terms kg table. Please confirm before publishing.
2. **STEP UP ≥25% threshold.** Brief cites 31.2% (7.2mg) vs 15.3% (2.4mg); project STEP UP doc cites **33.2% vs 16.7%**. Used project file figures. The brief itself flags that the Lancet categorical outcomes should be double-checked, so worth a final eyeball against the paper.
3. **STEP UP publication date.** Brief cites November 2025; project STEP UP doc cites September 2025 (*Lancet Diabetes & Endocrinology*). Used the project figure.
4. **"Needle-free auto-injector" claim dropped.** The brief's Mounjaro-vs-Wegovy section described Wegovy as having a needle-free auto-injector vs Mounjaro requiring needles. In fact, both now use pre-filled pens in the UK and the Wegovy FlexTouch requires a needle attachment. Left the comparison focused on cost and average weight loss to stay factually safe.
5. **CTA wording.** Replaced brief's "All-inclusive pricing, no hidden extras" with compliant framing per the Price & Membership Card, which explicitly bans that phrasing and requires shipping to be named as extra.
**Internal link substitutions** (brief URLs don't exist or aren't live per the URL map):
- Brief's `/pages/mounjaro-vs-wegovy-uk-2026` (Planned, not Live) → linked to `/blogs/news/what-is-wegovy-what-is-mounjaro` (Live) with anchor text "what Wegovy and Mounjaro are and how they work"
- Brief's `/pages/wegovy-uk-complete-guide-2026` (doesn't exist) → linked to `/blogs/news/wegovy-uk-a-complete-patient-guide-to-semaglutide-for-weight-loss` (Live) with anchor text "complete Wegovy guide"
- Brief's `/pages/mounjaro-uk-complete-guide-2026` (doesn't exist) → not used; the Mounjaro section is short enough not to need a link
- Brief's `/pages/medical-weight-loss-cost-uk-2026` (doesn't exist) → not used in this draft. If a cost link is wanted, `/blogs/news/wegovy-price-uk-2026-a-complete-guide-to-costs-titration-and-value` (Live) is the closest match.
**URL path and indexing.** Set up as a Shopify page at `/pages/how-much-weight-can-you-lose-on-wegovy` using the AEO article template, with `robots: noindex, follow` applied via the theme meta tag or Shopify SEO settings. The FAQPage and MedicalWebPage schemas still work on noindex pages: Google won't serve rich results, but AI engines (ChatGPT, Perplexity, Claude, Gemini) still parse the schema when crawling, which is the point. The `follow` directive ensures link equity still passes through to other Foundry pages linked from this article.
**MHRA safety.** Added a short "A note on safety" section above the FAQs, per the January 2026 MHRA update rule in the project instructions. An article on efficacy arguably doesn't trigger the full safety rule, but a brief, accurately-framed note is low-risk and protects the piece against MHRA scrutiny.
**Editorial checks.** Zero em dashes. Zero exclamation marks. UK English throughout. Sentence-case CTA button. Yellow Card link opens in a new window (HTML version). Contractions used naturally. No banned AI-tell words.
**Publish to:** `/pages/` on Shopify using the AEO article template. Page title field: *How Much Weight Can You Lose on Wegovy? (2026 Clinical Data)*. Meta title, description, and the `noindex, follow` robots directive are in the HTML comment block at the top of the HTML file.